Addex Therapeutics(US:ADXN)2022-03-09 16:00Financial Performance - Cash and cash equivalents increased to CHF 20.5 million at December 31, 2021, up from CHF 18.7 million at the end of 2020, representing an increase of CHF 1.8 million[9] - Total operating loss for 2021 was CHF 15.5 million, compared to CHF 12.2 million in 2020, reflecting an increase in R&D expenses[5] - Income decreased by CHF 0.7 million to CHF 3.2 million in 2021, down from CHF 3.9 million in 2020[7] - The net loss for the period was CHF 15.4 million in 2021, compared to CHF 12.9 million in 2020, with basic and diluted loss per share decreasing to CHF 0.45 from CHF 0.48[9] Research and Development - R&D expenses rose by CHF 2.4 million to CHF 12.8 million in 2021, primarily due to increased outsourced R&D costs[8] - The Phase 2 clinical trial for dipraglurant in blepharospasm is on track to report data in Q2 2022[3] - The Phase 2b/3 study for dipraglurant in dyskinesia associated with Parkinson's disease is expected to report data in H1 2023[3] - The Phase 2a clinical study of ADX71149 in epilepsy is on track to report data in Q3 2022[3] Strategic Collaborations and Funding - A strategic collaboration with Indivior was extended with an additional funding of $4 million[2] - The company completed the year with a strong cash position of $22.5 million, bolstered by a $10 million financing from Armistice Capital[2]